RELAYTO: Life Sciences Investor Experience White Paper

Insights from 102 life sciences founders, CEOs, and investors revealing why fundraising fails at conviction transfer — and how RELAYTO's connected evidence architecture transforms the investor experience from first outreach to formal diligence.